Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1986 1
1988 1
1990 1
1992 2
1993 1
1997 2
2000 1
2001 1
2003 2
2004 1
2005 2
2007 3
2008 2
2009 2
2010 6
2011 5
2012 4
2013 4
2014 4
2015 4
2016 1
2017 4
2018 3
2019 2
2020 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Isakoff MS, et al. J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304877 Free PMC article. Review.
However, the introduction of chemotherapy led to a dramatic improvement in prognosis for patients with localized osteosarcoma; long-term survival rates of less than 20% improved to 65% to 70% after the advent of multiagent chemotherapy regimens. ...Once promising ag …
However, the introduction of chemotherapy led to a dramatic improvement in prognosis for patients with localized osteosarcoma; …
Current and future therapeutic approaches for osteosarcoma.
Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Harrison DJ, et al. Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50. doi: 10.1080/14737140.2018.1413939. Epub 2017 Dec 14. Expert Rev Anticancer Ther. 2018. PMID: 29210294 Review.
This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients with metastatic or recurrent disease fare poorly with overall survival rates of less than 20%. ...A literature search was performed utilizing …
This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients wi …
Risk-Based Therapy for Localized Osteosarcoma.
Venkatramani R, Murray J, Helman L, Meyer W, Hicks MJ, Krance R, Lau C, Jo E, Chintagumpala M. Venkatramani R, et al. Pediatr Blood Cancer. 2016 Mar;63(3):412-7. doi: 10.1002/pbc.25808. Epub 2015 Oct 26. Pediatr Blood Cancer. 2016. PMID: 26501936 Free PMC article.
BACKGROUND: The outcome of localized osteosarcoma has remained constant over the past 30 years. ...CONCLUSIONS: Postoperative alkylator intensification with high-dose cyclophosphamide and melphalan in patients with localized osteosarcoma with poor hist …
BACKGROUND: The outcome of localized osteosarcoma has remained constant over the past 30 years. ...CONCLUSIONS: Postoperative …
New targets and approaches in osteosarcoma.
Gill J, Ahluwalia MK, Geller D, Gorlick R. Gill J, et al. Pharmacol Ther. 2013 Jan;137(1):89-99. doi: 10.1016/j.pharmthera.2012.09.003. Epub 2012 Sep 14. Pharmacol Ther. 2013. PMID: 22983152 Review.
Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. ...
Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma c …
MFH of bone and osteosarcoma show similar survival and chemosensitivity.
Jeon DG, Song WS, Kong CB, Kim JR, Lee SY. Jeon DG, et al. Clin Orthop Relat Res. 2011 Feb;469(2):584-90. doi: 10.1007/s11999-010-1428-z. Epub 2010 Jun 18. Clin Orthop Relat Res. 2011. PMID: 20559764 Free PMC article.
PATIENTS AND METHODS: We retrospectively compared 27 patients with Stage IIB MFH-B with 389 patients with localized osteosarcoma for initial tumor volume, age, histologic response, and survival. ...CONCLUSIONS: Patients with MFH-B and osteosarcoma have similar survi …
PATIENTS AND METHODS: We retrospectively compared 27 patients with Stage IIB MFH-B with 389 patients with localized osteosarcoma …
Maintenance therapy and drug holiday in sarcoma patients: systematic review.
Lebellec L, Defachelles AS, Cren PY, Penel N. Lebellec L, et al. Acta Oncol. 2020 Sep;59(9):1084-1090. doi: 10.1080/0284186X.2020.1759825. Epub 2020 May 13. Acta Oncol. 2020. PMID: 32400254
After classical chemotherapy, maintenance therapy with immune-stimulating agents for localized osteosarcoma, bevacizumab for advanced angiosarcoma or pediatric advanced sarcoma, or mTOR inhibitors for metastatic sarcoma does not improve the outcome. ...
After classical chemotherapy, maintenance therapy with immune-stimulating agents for localized osteosarcoma, bevacizumab for a …
Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA, Chou AJ. Meyers PA, et al. Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Adv Exp Med Biol. 2014. PMID: 24924182 Review.
Phase II studies showed decreased risk of further recurrence in patients who received mifamurtide after surgical ablation of metastatic osteosarcoma. A phase III prospective randomized trial demonstrated a statistically significant reduction in the risk of death fro …
Phase II studies showed decreased risk of further recurrence in patients who received mifamurtide after surgical ablation of metastatic oste …
Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: a systemic review and meta-analysis of cohort studies.
Sun L, Li Y, Zhang J, Li H, Li B, Ye Z. Sun L, et al. J Orthop Res. 2015 Jan;33(1):131-9. doi: 10.1002/jor.22734. Epub 2014 Sep 18. J Orthop Res. 2015. PMID: 25231396 Free article. Review.
The overall relative risk (RR) was estimated using a fixed-effect model or random-effect model according to heterogeneity between the trials. ...
The overall relative risk (RR) was estimated using a fixed-effect model or random-effect model according to heterogeneity between the …
Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE. Frampton JE. Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000. Paediatr Drugs. 2010. PMID: 20481644 Review.
In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma. In a large, randomized, open-label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three- or four-dru …
In the US, mifamurtide is currently an investigational agent that holds orphan drug status for the treatment of osteosarcoma. In a large, …
Poor prognosis osteosarcoma: new therapeutic approach.
Fagioli F, Biasin E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M, Madon E. Fagioli F, et al. Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S131-4. doi: 10.1038/bmt.2008.71. Bone Marrow Transplant. 2008. PMID: 18545234 Review.
Over the past 30 years, a significant improvement in the prognosis of localized osteosarcoma of the extremities has been observed. Despite these results, approximately 30-40% of patients will relapse, mostly within the first 3 years from diagnosis. ...
Over the past 30 years, a significant improvement in the prognosis of localized osteosarcoma of the extremities has been obser …
56 results